Other molecules activating THRβ signalling have been tested with discrete results in animal models, such as TG68, which ameliorates hepatic steatosis and lipid metabolism, mainly improving mitochondrial fatty acid oxidation downstream the activation of THRβ [171], or KBP-089, a double-receptor agonist for amylin and calcitonin, a hormone secreted by thyroid C cells, which seems to ameliorate the lipid profile, especially when in combination therapy with liraglutide [172,173], but these studies are still at their beginnings. The gene discussed is THRB; the disease is fatty liver disease.